We've been doing product R&D and clinical projects consulting since 2013. Our successes have been in birthing fresh ideas, innovative designs and highly-scalable deployments for our blockchained healthcare-AI-powered platform (SaaS) ClinicalTrials360 . It's based on and powered by our general-purpose AI platform myai.expert.
This project is in honor of all our healthcare caregivers worldwide. We were founded as a boutique, responsive, pro-active, diversity-inclusive and responsible research and development shop. We've worked for the largest healthcare and other industry established players and companies and have honed our development, product and services and marketing deliveries and business administration skills.
It started from a whiteboard idea for a post-grad project late 2012 and early 2013 and took off in earnest by summer 2013.
We then evolved into a major set of clinical pipeline workflows, apps, databases, IoT, automations (RPA), e-Learning, e-certifications, SaaS, APIs and clinical consulting. Finally, to an integrated platform with AI, blockchain and many other awesome technologies and fully-developed , tested and deployed techstacks!
We Release ONLY When Fully Ready - No Vaporware
We didn't want to file for our first OPO until we had a SOLID working, stable product and at least two solid years of earnings that paid our bills at our Lisaiceland venue (Texas DBA) from doing clinical consulting work. This is how we paid the development bills. Raw hard work and some conservative bootstrapped financial smarts.
The Release Candidate 0 (or RC0) for user acceptance testing (UAT) started in earnest on February 01, 2018.
Today our platform (SaaS - software as a service) exists in its first major Release Candidate (RC) RC0 as a highly-scalable SaaS bringing together:
The platform has already gone through nearly four plus years of solid R and D and testing in the Contract Research Organization healthcare specialty area (CRO - i.e. organization that does clinical trials for drug and medical devices sponsor companies).
We wanted to make a difference in solving MAJOR pain-points, one being research that does not end up in practice.
Investment
$0.19 per share For Common Stock
When you invest you are betting the company’s future value will
exceed $18.3M.
Perks*
$500+ — If you invest $500 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $50 cash gift card. PLUS all stock purchases has a 10% discount attached to it.
$5,000+ — If you invest $5,000 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $200 cash gift card. PLUS all stock purchases has a 10% discount attached to it.
$10,000+ — If you invest $10,000, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $300 cash gift card. PLUS all stock purchases has a 10% discount attached to it.
*All perks occur after the offering campaign is completed
We have developed ClinicalTrials360 powered by our general-purpose AI-platform myai.expert, a blockchain-secured, AI-based platform (SaaS). It is out in solid beta release candidate trials right now as of February 01, 2018. It's built to handle massive amounts of HIPAA and GCP-secured Healthcare data for AI-based data-analytics and extraction of hidden clinical insights. More specifically, data for Clinical Trials Data Management (CTDM). This includes actual trials data and we're developing the next round of products to allow the initial pathology and therapeutics-based data analytics that will be consumed by our AI engine to generate significant insights and allowing the reduction of targets-choosing by PIs (Principal Investigators, i.e. Doctors, Medical Researchers, Chief RNs). We forecast that this reduction will be from six years average currently to under one year. We are in a race to achieve this over the next 1-3 years maximum with a production version integrated into our CTDM.
The uses for both ClinicalTrials360 and general AI platform myai.expert are way beyond this and has a very bright future!
Please Note: Clinical Trials refers to human-based trials of drug-therapies and/or medical devices. Combinations of these are also possible in any Clinical Trials.
We are doing more major iterations in 2018 and beyond to make it a unique offering solving challenges in Clinical Trials Data Management, incorporating full clinical data management (CDM) workflow, AI machine and deep-learning, e-Learning and e-Certifications and secured by our own private blockchain. We have implemented innovative design ideas to make the platform very easily-tweakable (by our development team and users) and highly scalable and operating in the cloud.
Historical Numbers So Far:
Lisaiceland® (unincorporated)
Texas DBA
Clinical Trials Consulting Completed successfully for
2016 and 2017
2016
CLINICAL TRIALS MANAGEMENT CONSULTING
USING WORKING POC
Revenue = $78,196
2017
CLINICAL TRIALS MANAGEMENT CONSULTING
USING WORKING POC
Revenue = $73,060
Let's Do All We Can To Help Save!
Each year Billions are spent researching clinical treatments, but a staggering 85% of all research ends up not being put into practice – much of it passed over for reasons that could be avoided. Even when research findings are taken up by clinicians and those in charge of health policy, the average delay between publication and practice is 17 years. (See Here)
Our Internal Active-Measures (Company Administration Model)
We've kept our costs, payroll and expenses to a minimum and have completed the first stable release candidate (RC) iteration for our platform. We're very practical and produce real products and services at all times. Zero-hype. All results. Our past performance, products and current iterations speak for themselves. We aim to deliver WORKING products and services of the highest quality.
We aim to maximize our expenditures in marketing our platform and maximize our profits. All current teammates are remote and on contract probation until the company achieves at least $5M in funding, revenue or a combination of both by Q4 2018.
Our focus is making all phases of clinical trials more efficient: design, actively running with PIs (principal investigators) and the full 360-degrees coverage of studies' and sites' operations, onsite-training, e-Learning, consulting and full clinical data management to final delivery.
Our efforts encompass working with other expert CROs, CRAs, CRCs, CDMs, PIs and bio pharmaceutical and medical device development sponsors.
Healthcare: CTDM Use-Case
Black & White
Why would you need or even desire more efficient clinical trials data management (CTDM) run on our platform? Plus, all this with related results for design, planning, setup, reporting, auditing, analytics, tracking and patient supervision - before, during and way after a trial is over?
Short Answer
Better 360°-Managed LIVE Clinical Trials (Data Management) and Much Better Final Workflows.
Collectively
Save More Lives. Period.
Study Signup
aiSuperStudy
Get Secure Workspace
Login
Enter Your
Study Data
Manage
Your CDM
Workflow + Users
The number of clinical trials has doubled from 2011 to 2018 (March 25).
ClinicalTrials.gov currently lists 269,430 studies with locations in all 50 States and in 203 countries. (See Here)
Typical Clinical Trials Costs: See Here
Total costs for each of the therapeutic areas included in our model by clinical trial phase (assuming one trial per phase and not inclusive of failures):
Immunomodulation per-study costs ($6.6 million) are the highest in Phase 1 with costs of studies in ophthalmology ($5.3 million) and respiratory system ($5.2 million) ranking second and third, respectively.
Hematology trial costs ($19.6 million) rank first, followed by pain and anesthesia ($17.0 million) and immunomodulation ($16.0 million).
The most costly studies are in pain and anesthesia ($52.9 million) with studies in ophthalmology ($30.7 million) and cardiovascular ($25.2) area ranking second and third, respectively.
Respiratory system trial costs ($72.9 million) rank first, followed by oncology ($38.9 million) and pain and anesthesia ($32.1 million) study costs.
Overall, the therapeutic area with the highest clinical research burden across all phases is respiratory system ($115.3 million) followed by pain and anesthesia ($105.4 million) and oncology ($78.6 million) trials (see Figure 3). On the other hand, trials in central nervous system, dermatology, and genitourinary system tend to cost the least overall. (see: https://goo.gl/osfV1H)
What's worse is that this cost is increasing rapidly.
More than $7 of every $10 dollars is spent on administrative staff, clinical procedures, site monitoring and site retention.
(see: https://goo.gl/NMycDL)
Great data management using our CTDM (aiSuperStudy + aiCTDM) system can drastically reduce that, reduce errors and become an integral part of a futuristic and highly-scalable system that not solves current clinical data management pain-points but also has AI insights and blockchain security as added (huge) benefits.
We have taken aim squarely to make trials workflows more efficient so that the above IMMENSE costs can be lowered. That's the first order of the day.
Designing and running successfully a Clinical Trial workflow (aka pipeline) is a tough job and it requires significant amount of data:
To determine which method or strategy is going to be the best for the drug at hand. It is a very people-intensive activity and contrary to popular understanding for clinical trials and healthcare in general, it is NOT a technology-intensive domain.
The setup of a Clinical Trial involves a lot of things:
Recruitment of test subjects, administration, reporting, compliance, etc. The usage of data and technology, specifically AI machine and deep learning and e-learning, e-certifications and e-completions (i.e. actually running the trials) for better predictability of outcomes and generation of actionable-insights is critical in this step and deploying a conventional setup is not possible anymore.
This is one of the biggest problems Clinical Trial Teams face:
Tracking the dosage and reactions of their trial patients. Even though phone calls, clinic visits and even video documentation helps, it doesn't really solve the problem significantly.
One of the biggest problems in clinical trials is reporting.
Representation of data, results, conclusions and then extracting the results from that data, all of this affects the efficacy and efficiency of the trials themselves and may even lead to inefficient data for future research and ongoing work as well. (See Here)
How does one verify the trial results?
Who was responsible for which step? Auditing in a nightmare for any business or process, but auditing a Clinical Trial that is responsible for the lives of people is a whole different ball game.
We believe that Better CTDM results lead to better implementations driving down key cost drivers for newer innovative therapies and drugs.
The increasing cost of clinical research has significant implications for public health, as it affects drug companies' willingness to undertake clinical trials, which in turn limits patient access to novel treatments. (See Here)
The cost of failed clinical trials is very high. Estimates vary on the cost of a failed clinical trial, but figures range anywhere from $800 million to $1.4 billion
(See Here)
Hence, we have created a blockchain plus AI-powered SaaS that helps CROs, users, admins, researchers and patients across the world conduct efficient, cost-effective and easy to manage Clinical Trials.
The current state for a single clinical trials data management "system-of-record" that's powered by an Blockchained-AI platform is:
2017 to 2025: The market is expected to be dominated by Phase III as of 2016, with Phase I anticipated to witness the fastest growth
Increasing innovation and evolution of treatment is predicted to contribute towards growth of the expanded access trials segment
Oncology: Based on indication, the oncology segment is anticipated to witness the fastest growth.
Preclinical, Oncology-Focused: According to various sources, more than USD $38.0 billion is currently being spent by the healthcare industry towards preclinical and clinical development of oncology therapy products
North America #1 Market: North America dominated the overall market in terms of revenue share in 2015 owing to the presence of big outsourcing firms and increasing R&D in the region.
Key players: Quintiles IMS, Paraxel International Corporation, Charles River Laboratories, ICON plc, SGS SA among the others dominate the global clinical trials market while (note: this is representing maximum volume in 2016)
Another More Detailed Report Here:
Clinical Trials Market Analysis By Phase (Phase I/II/III/IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Autoimmune, Pain management, Oncology, CNS condition, Diabetes, Obesity), And Segment Forecasts, 2014 - 2025
Our Main Reference Data-Points Considered:
U.S. clinical trials market, by phase, 2014 - 2025 (USD Billion)
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Lisaiceland Inc.® is proud to announce the release of the latest iteration of myai.expert® ClinicalTrials360® platform! It is a full Blockchained Democratized Healthcare-AI SaaS. The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.
Maximum [563,157] shares of common stock ($106,999.83)
Minimum [52,631] shares of common stock ($9,999.89)
| Company | Lisaiceland Inc. |
| | |
| Corporate Address | Mailing Address: Lisaiceland Inc. C/O: Lisa Kristinardottir 22136 Westheimer Parkway, Katy, Texas, 77450 |
| | |
| Description of Business | Blockchained Democratized Healthcare-AI Platform (SaaS) with Integrated Healthcare CRO and Staffing Services |
| | |
| Type of Security Offered | Common Stock |
| | |
| Purchase Price of Security Offered | $0.19 / Per Share |
| | |
| Minimum Investment Amount (per investor) | Minimum $499.89 |
Perks
$500+ — If you invest $500 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $50 cash gift card. PLUS all stock purchases has a 10% discount attached to it.
$5,000+ — If you invest $5,000 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $200 cash gift card. PLUS all stock purchases has a 10% discount attached to it.
$10,000+ — If you invest $10,000, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $300 cash gift card. PLUS all stock purchases has a 10% discount attached to it.
*All perks occur after the offering is completed
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Follow Lisaiceland to get notified of future updates!
Comments ({{profileCtrl.startup.comments_count}} total)
Show More Comments